To observe the clinical efficacy of Modified Huoluo Xiaoling Formula（活络效灵方加减）in the treatment of stasis-type rheumatoid arthritis（RA）.

The time period of case selection was from January 2022 to December 2023, and the study population consisted of 120 patients with stasis-type RA attending the Bozhou People＇s Hospital, which was divided into two groups by simple randomisation method. The control group was treated with methotrexate combined with leflunomide, while the observation group was treated on the basis of the control group with Modified Huoluo Xiaoling Formula, and the medication was administered for 12 consecutive weeks. The two groups were compared in terms of TCM symptom scores, erythrocyte sedimentation rate（ESR）, anti-cyclic peptide containing citrulline（CCP）, interleukin-6（IL-6）and rheumatoid factor（RF）. The differences in visual analogue scale（VAS）scores, Disease Activity Score using 28 joints（DAS28）scores were assessed between the two groups, and the overall clinical effective rate and incidence were analyzed.

There was no significant difference in TCM syndrome scores between the two groups before treatment（P > 0.05）. Compared with those before treatment, the scores of joint swelling, tenderness, morning stiffness, deformity, muscle tenderness, limited flexion and extension, pale complexion and dry skin were lower in both groups after 12 weeks of treatment. The observation group had lower scores than the control group after 12 weeks of treatment（P < 0.05）. There was no significant difference in ESR, anti-CCP antibodies, IL-6 or RF between the two groups before treatment（P > 0.05）. Compared with those before treatment, the levels of anti-CCP antibodies, IL-6, ESR and RF were lower in both groups after 12 weeks of treatment, with the observation group having lower levels than the control group（P < 0.05）. There was no significant difference in DAS28 scores or VAS scores between the two groups before treatment（P > 0.05）. Compared with those before treatment, the DAS28 scores and VAS scores were lower in both groups after 12 weeks of treatment, with the observation group having lower scores than the control group（P < 0.05）. The clinical effectiveness rate in the observation group was 93.33%, higher than 80.00% in the control group, with a significant difference（P < 0.05）.

The treatment of stasis-type RA with Modified Huoluo Xiaoling Formula can reduce the levels of ESR, anti-CCP antibody, IL-6 and RF, and improve the therapeutic efficacy.